SEARCH

SEARCH BY CITATION

References

  • Amenta F., Di Tullio M. A. and Tomassoni D. (2003) Arterial hypertension and brain damage-evidence from animal models. Clin. Exp. Hypertens. 25, 359380.
  • Argmann C. A., Cock T. A. and Auwerx J. (2005) Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur. J. Clin. Invest. 35, 8292.
  • Arsenijevic D., De Bilbao F., Plamondon J., Paradis E., Vallet P., Richard D., Langhans W. and Giannakopoulos P. (2006) Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J. Cereb. Blood Flow Metab. 26, 433445.
  • Bergeron M., Yu A. Y., Solway K. E., Semenza G. L. and Sharp F. R. (1999) Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischemia in rat brain. Eur. J. Neurosci. 11, 41594170.
  • Blanco M., Moro M. A., Davalos A., Leira R., Castellanos M., Serena J., Vivancos J., Rodriguez-Yanez M., Lizasoain I. and Castillo J. (2005) Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 36, 11891194.
  • Blanquart C., Barbier O., Fruchart J. C., Staels B. and Glineur C. (2003) Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85, 267273.
  • Bowen K. K., Tureyen K., Kalluri H., Svaren J. and Vemuganti R. (2005) Egr1 null mice show curtailed inflammatory gene expression and significant neuroprotection following transient focal ischemia. Soc. Neurosci. Abst. 31, 97.1.
  • Breidert T., Callebert J., Heneka M. T., Landreth G., Launay J. M. and Hirsch E. C. (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson’s disease. J. Neurochem. 82, 615624.
  • Cheng-Lai A. and Levine A. (2000) Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis. 2, 326333.
  • Cho S., Park E. M., Kim Y., Liu N., Gal J., Volpe B. T. and Joh T. H. (2001) Early c-Fos induction after cerebral ischemia: A possible neuroprotective role. J. Cereb. Blood Flow Metab. 21, 550556.
  • Cortes-Canteli M., Wagner M., Ansorge W. and Perez-Castillo A. (2004) Microarray analysis supports a role for CCAAT/enhancer-binding protein-beta in brain injury. J. Biol. Chem. 279, 14 40914 417.
  • Dello Russo C., Gavrilyuk V., Weinberg G., Almeida A., Bolanos J. P., Palmer J., Pelligrino D., Galea E. and Feinstein D. L. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278, 58285836.
  • Deplanque D., Gele P., Petrault O. et al. (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23, 62646271.
  • Dhodda V. K., Sailor K. A. and Vemuganti R. (2004) Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J. Neurochem. 89, 7389.
  • Diab A., Hussain R. Z., Lovett-Racke A. E., Chavis J. A., Drew P. D. and Racke M. K. (2004) Ligands of the peroxisome proliferators-activated receptor-gamma and retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalopathy. J. Neuroimmunol. 148, 116126.
  • Dogan A., Baskaya M. K., Rao V. L., Rao A. M. and Dempsey R. J. (1998) Intraluminal suture occlusion of the middle cerebral artery in Spontaneously Hypertensive rats. Neurol. Res. 20, 265270.
  • Escher P. and Wahli W. (2000) Peroxisome proliferators-activated receptors: insights into multiple cellular functions. Mutation Res. 448, 121138.
  • Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V. and Dello Russo C. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70, 177188.
  • Graham S. H and Hickey R. W (2003) Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch. Neurol. 60, 628630.
  • Hu B. R., Liu C. L. and Park D. J. (2000) Alteration of MAP kinase pathways after transient forebrain ischemia. J. Cereb. Blood Flow Metab. 20, 10891095.
  • Iadecola C. and Gorelick P. B. (2005) The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke 36, 182185.
  • Iadecola C., Salkowski C. A., Zhang F., Aber T., Nagayama M., Vogel S. N. and Ross M. E. (1999) The transcription factor interferon regulatory factor-1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J. Exp. Med. 189, 719727.
  • Ichikawa H., Naito Y., Takagi T., Tomatsuri N., Yoshida N. and Yoshikawa T. (2002) A specific peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 7, 343346.
  • Kapadia R., Tureyen K., Bowen K., Kalluri H., Johnson P. F. and Vemuganti R. (2006) Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J. Neurochem. (in press).
  • Kiec-Wilk B., Dembinska-Kiec A., Olszanecka A., Bodzioch M. and Kawecka-Jaszcz K. (2005) The selected pathophysiological aspects of PPARs activation. J. Physiol. Pharmacol. 56, 149162.
  • Lu A., Tang Y., Ran R., Clark J. F., Aronow B. J. and Sharp F. R. (2003) Genomics of the periinfarction cortex after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23, 786810.
  • Luo Y., Yin W., Signore A. P., Zhang F., Hong Z., Wang S., Graham S. H. and Chen J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferators-activated receptor-γ agonist rosiglitazone. J. Neurochem. 97, 435448.
  • MacManus J. P., Graber T., Luebbert C., Preston E., Rasquinha I., Smith B. and Webster J. (2004) Translation-state analysis of gene expression in mouse brain after focal ischemia. J. Cereb. Blood Flow Metab. 24, 657667.
  • Maeda K., Hata R., Gillardon F. and Hossman K. A. (2001) Aggravation of brain injury after focal cerebral ischemia in p53-deficient mice. Mol. Brain Res. 88, 5461.
  • Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M. and Tanayama S. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47, 2935.
  • McCulloch J. (1996) Neuroprotective drug development in stroke: blood pressure and its impact. J. Hypertens. 14, S1318.
  • Naylor M., Bowen K. K., Sailor K. A., Dempsey R. J. and Vemuganti R. (2005) Preconditioning-induced ischemic tolerance stimulates growth factor expression and neurogenesis in adult rat hippocampus. Neurochem. Int. 47, 565572.
  • Okada M., Yan S. F. and Pinsky D. J. (2002) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J. 16, 18611868.
  • Park E. J., Park S. Y., Joe E. H. and Jou I. (2003) 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem. 278, 14 74714 752.
  • Pereira M. P., Hurtado O., Cardenas A. et al. (2006) Rosiglitazone and 15-deoxy-Delta12,14-prostagliandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26, 218229.
  • Rakesh K. and Agarwal D. K. (2005) Controlling cytokine signaling by constitutive inhibitors. Biochem. Pharmacol. 70, 649657.
  • Rickhag M., Wieloch T., Gido G. et al. (2006) Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue. J. Neurochem. 96, 1429.
  • Rodrigo J., Fernandez A. P., Serrano J., Peinado M. A. and Martinez A. (2005) The role of free radicals in cerebral hypoxia and ischemia. Free Radic. Biol. Med. 39, 2650.
  • Saito A., Maier C. M., Narasimhan P. et al. (2005) Oxidative stress and neuronal death/survival signaling in cerebral ischemia. Mol. Neurobiol. 31, 105116.
  • Satriotomo I., Bowen K. and Vemuganti R. (2006) JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia. J. Neurochem. 98, 13531368.
  • Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G. E., Schurmann B., Zimmer A. and Heneka M. T. (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 78057812.
  • Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H. and Greenberg J. H. (2005) A peroxisome proliferators-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36, 353359.
  • Stephenson D., Yin T., Smalstig E. B., Hsu M. A., Panetta J., Little S. and Clemens J. (2000) Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 20, 592603.
  • Sundararajan S., Gamboa J. L., Victor A. N., Wanderi E. W., Lust W. D. and Landreth G. E. (2005) Peroxisome proliferation-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130, 685696.
  • Swanson R. A., Morton M. T., Tsao-Wu G., Savalos R. A., Davidson C. and Sharp F. R. (1990) A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10, 290293.
  • Tanaka K., Nogawa S., Ito D., Suzuki S., Dembo T., Kosakai A. and Fukuchi Y. (2000) Activated phosphorylation of cyclic AMP response element binding protein is associated with preservation of striatal neurons after focal cerebral ischemia in the rat. Neuroscience 100, 345354.
  • Tolman K. G. and Chandramouli J. (2003) Hepatotoxicity of the thiazolidinediones. Clin. Liver Dis. 7, 369379.
  • Tureyen K., Vemuganti R., Sailor K., Bowen K. K. and Dempsey R. J. (2004) Transient focal cerebral ischemia-induced neurogenesis in the dentate gyrus of the adult mouse. J. Neurosurg. 101, 799805.
  • Vemuganti R. and Dempsey R. J (2005) Carotid atherosclerotic plaques from symptomatic stroke patients share the molecular fingerprints to develop in a neoplastic fashion: a microarray analysis study. Neuroscience 131, 359374.
  • Vemuganti R., Dogan A., Bowen K. K. and Dempsey R. J. (2001) Ornithine decarboxylase knockdown exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. J. Cereb. Blood Flow Metab. 21, 945954.
  • Vemuganti R., Bowen K. K., Dhodda V. K., Song G., Franklin J. L., Gavva N. R. and Dempsey R. J. (2002) Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J. Neurochem. 83, 10721086.
  • Vemuganti R., Dempsey R. J. and Bowen K. K. (2004) Inhibition of ICAM-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 35, 179184.
  • Vemuganti R., Satriotomo I. and Bowen K. K. (2005) Role of STAT/SOCS signaling in controlling stroke-induced inflammation and brain damage. J. Neurochem. 94, 117.
  • Vemuganti R., Kalluri H., Bowen K. K., Yi J. H. and Hazell A. S. (2006) Gene expression changes in thalamus and inferior colliculus associated with inflammation, cellular stress, metabolism and structural damage in thiamine deficiency. Eur. J. Neurosci. 23, 11721188.
  • Watson G. S., Cholerton B. A., Reger M. A. et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnesic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. J. Geriatr. Psychiatry 13, 950958.
  • Wayman N. S., Hattori Y., McDonald M. C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P. K. and Thiemermann C. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J. 16, 10271040.
  • Williams A. J., Hale S. L., Moffett J. R., Dave J. R., Elliott P. J., Adams J. and Tortella F. C. (2003) Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via anti-inflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J. Cereb. Blood Flow Metab. 23, 7587.
  • Yan S. F., Fujita T., Lu J., Okada K., Shan Zou Y., Mackman N., Pinsky D. J. and Stern D. M. (2000) Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nature Med. 6, 13551361.
  • Yan Y. P., Sailor K. A., Vemuganti R. and Dempsey R. J. (2006) Insulin-like growth factor-1 is an endogenous mediator of focal ischemia-induced neural progenitor proliferation. Eur. J. Neurosci. 24, 4554.
  • Zea Longa E., Weinstein P. R., Carlson S. and Cummins R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rat. Stroke 20, 8491.
  • Zhao X., Zhang Y., Strong R., Grotta J. C. and Aronowski J. (2006a) 15d-Prostaglandin J2 activates peroxisome proliferators-activated receptor-γ, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J. Cereb. Blood Flow Metab. 26, 811820.
  • Zhao Y., Patzer A., Herdegen T., Gohlke P. and Culman J. (2006b) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J. 20, 11621175.
  • Zheng Z., Lee J. E. and Yenari M. A. (2003) Stroke: Molecular mechanisms and potential targets for treatment. Curr. Mol. Med. 3, 361372.